Miyazaki M, Ichikawa S, Onishi Y, Fukuhara N, Furukawa E, Onodera K
J Clin Exp Hematop. 2022; 62(3):164-168.
PMID: 35732409
PMC: 9635028.
DOI: 10.3960/jslrt.22003.
Savani M, Ahn K, Chen Y, Ahmed S, Cashen A, Shadman M
Br J Haematol. 2022; 197(2):212-222.
PMID: 35106754
PMC: 9018546.
DOI: 10.1111/bjh.18052.
Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich C, Finel H
Blood Adv. 2021; 6(3):920-930.
PMID: 34861680
PMC: 8945300.
DOI: 10.1182/bloodadvances.2021005899.
Roerden M, Walz J, Muller M, Sokler M, Federmann B, Kanz L
J Cancer Res Clin Oncol. 2019; 145(10):2595-2604.
PMID: 31410605
DOI: 10.1007/s00432-019-02999-9.
Epperla N, Ahn K, Litovich C, Ahmed S, Battiwalla M, Cohen J
J Hematol Oncol. 2019; 12(1):6.
PMID: 30630534
PMC: 6329157.
DOI: 10.1186/s13045-018-0696-z.
Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation.
Huang W, Liu D
Chin Med J (Engl). 2018; 131(17):2105-2111.
PMID: 30127221
PMC: 6111674.
DOI: 10.4103/0366-6999.239315.
A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas.
Kaito S, Kanemasa Y, Sasaki Y, Okuya T, Yamaguchi T, Funasaka C
Int J Hematol. 2017; 107(4):451-459.
PMID: 29103138
DOI: 10.1007/s12185-017-2362-6.
Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?.
Kharfan-Dabaja M, El-Jurdi N, Ayala E, Kanate A, Savani B, Hamadani M
Bone Marrow Transplant. 2017; 52(11):1487-1494.
PMID: 28368373
DOI: 10.1038/bmt.2017.55.
Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.
Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P
Cochrane Database Syst Rev. 2013; (8):CD008908.
PMID: 23986525
PMC: 7156921.
DOI: 10.1002/14651858.CD008908.pub3.
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.
Kanakry J, Kasamon Y, Gocke C, Tsai H, Davis-Sproul J, Ghosh N
Biol Blood Marrow Transplant. 2013; 19(4):602-6.
PMID: 23370119
PMC: 4020434.
DOI: 10.1016/j.bbmt.2013.01.006.
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Zain J, Palmer J, Delioukina M, Thomas S, Tsai N, Nademanee A
Leuk Lymphoma. 2011; 52(8):1463-73.
PMID: 21699453
PMC: 3441144.
DOI: 10.3109/10428194.2011.574754.
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Smits E, Lee C, Hardwick N, Brooks S, Van Tendeloo V, Orchard K
Cancer Immunol Immunother. 2011; 60(6):757-69.
PMID: 21519825
PMC: 11029703.
DOI: 10.1007/s00262-011-1022-6.
Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.
Delioukina M, Zain J, Palmer J, Tsai N, Thomas S, Forman S
Bone Marrow Transplant. 2011; 47(1):65-72.
PMID: 21358679
PMC: 3130104.
DOI: 10.1038/bmt.2011.16.
Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas.
Reimer P
Adv Hematol. 2011; 2010:320624.
PMID: 21253465
PMC: 3022174.
DOI: 10.1155/2010/320624.
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J
Biol Blood Marrow Transplant. 2010; 16(11):1467-503.
PMID: 20699125
PMC: 2955517.
DOI: 10.1016/j.bbmt.2010.08.001.
